Panbela Therapeutics Defaults on Material Obligations Leading to Investor ActionOn January 20, 2025, Panbela Therapeutics, Inc. submitted a Form 8-K filing to the Securities and Exchange Commission (SEC) reporting an event of default. The company inf

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Panbela Therapeutics’s 8K filing here.

Panbela Therapeutics Company Profile

Panbela Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company’s lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial.